Caricamento...
A phase II study of laquinimod in Crohn's disease
OBJECTIVE: Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple sclerosis. This dose escalation study evaluated the safety and efficacy of laquinimod as induction therapy in patients with a...
Salvato in:
| Pubblicato in: | Gut |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4515993/ https://ncbi.nlm.nih.gov/pubmed/25281416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2014-307118 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|